phrykt

Gilead Sciences (GILD) revenue: $29.4B

Gilead Sciences reported $29.4B of revenue for the year ended Dec 31, 2025, up 2.4% from $28.8B a year earlier.

From Gilead Sciences's filings with the SEC · Read the filing · GILD stock page

Gilead Sciences revenue by year

$27.3B2021$27.3B2022$27.1B2023$28.8B2024$29.4B2025

#148 of 3,623 US companies by revenue · See the full ranking

Year endedRevenueChange
Dec 31, 2025$29.4B+2%
Dec 31, 2024$28.8B+6%
Dec 31, 2023$27.1B-1%
Dec 31, 2022$27.3B-0%
Dec 31, 2021$27.3B–

Revenue of similar companies

Companies in the same industry as Gilead Sciences, by SEC industry code, with the closest revenue. Each name opens the same page for that company.

CompanyRevenue, latest yearYear ended
Amgen$36.8BDec 31, 2025
Gilead Sciences$29.4BDec 31, 2025
Biogen$9.9BDec 31, 2025
Neurocrine Biosciences$2.9BDec 31, 2025
Exelixis$2.3BJan 2, 2026
Qiagen$2.1BDec 31, 2025
Moderna$1.9BDec 31, 2025

Questions and answers

What is Gilead Sciences's revenue?

Gilead Sciences reported $29.4B of revenue for the year ended Dec 31, 2025, up 2.4% from $28.8B a year earlier.

Numbers as reported in Gilead Sciences's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology